ProMIS Neurosciences

ProMIS Neurosciences Debt

Delisted

Debt of ProMIS Neurosciences (PMN.TO) as of Nov 4, 2026.

Debt

0.00CAD

Last updated:

In 2022, ProMIS Neurosciences's total debt was 0.00 CAD, a % change from the 3.91 M CAD total debt recorded in the previous year.

The ProMIS Neurosciences Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2015
120,000.00 CAD
Jan 1, 2016
120,000.00 CAD
Jan 1, 2017
0.00 CAD
Jan 1, 2018
0.00 CAD
Jan 1, 2019
0.00 CAD
Jan 1, 2020
0.00 CAD
Jan 1, 2021
3.91 M CAD
Jan 1, 2022
0.00 CAD
The ProMIS Neurosciences Debt history
YEARDebtYoY
0.00CAD-100.00%
3.91 MCAD—
0.00CAD—
0.00CAD—
0.00CAD—
0.00CAD-100.00%
120,000.00CAD0.00%
120,000.00CAD—
0.00CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ProMIS Neurosciences Stock analysis

What does ProMIS Neurosciences do? ProMIS Neurosciences Inc is a biopharmaceutical company based in Canada that specializes in the discovery and development of novel therapeutics for neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. The company was founded in 2004 and has been listed on the Toronto Stock Exchange since 2015. The goal of ProMIS is to develop highly specific therapeutics that specifically target the cellular causes of neurodegenerative diseases and can therefore stop or even reverse the progression of the disease. The company utilizes its proprietary platform technology to identify the unique epitopes on the pathological proteins that are specific to neurodegenerative diseases. ProMIS' business model is based on partnerships with large pharmaceutical companies that are searching for new therapeutics for neurodegenerative diseases. ProMIS works closely with these partners to develop customized therapeutics tailored to each partner's specific needs. The company licenses its technology and products to its partners and receives license and milestone payments when certain development or sales goals are achieved. ProMIS has different divisions to focus on various neurodegenerative diseases, with a focus on Alzheimer's, Parkinson's, and ALS. ProMIS has a comprehensive research and development infrastructure that focuses on the identification, characterization, and optimization of therapeutic antibodies and biomarkers. In terms of products, ProMIS has developed various antibodies that specifically target pathological proteins such as Aß and Tau in Alzheimer's and alpha-synuclein in Parkinson's. These antibodies can selectively recognize and bind to these pathological proteins, allowing them to be broken down and removed from the body. ProMIS works closely with its partners to test these antibodies in clinical trials and eventually bring them to market. In addition to its antibody products, ProMIS has also developed neuromethods that allow researchers to characterize and quantify the functions of proteins in brain cells and in vivo. These methods can be used to test and optimize the effects of antibodies and other therapeutics, making them an important part of ProMIS' development infrastructure. Overall, ProMIS Neurosciences Inc is an innovative biopharmaceutical company that focuses on the development of highly specific therapeutics for neurodegenerative diseases. The company has a comprehensive infrastructure and technology platform that allows it to develop customized products for its partners. With its antibodies and neuromethods, ProMIS has the potential to make a breakthrough in the treatment of neurodegenerative diseases and improve the lives of millions of patients. ProMIS Neurosciences is one of the most popular companies on Eulerpool.

Debt Details

Understanding ProMIS Neurosciences's Debt Structure

ProMIS Neurosciences's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing ProMIS Neurosciences's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to ProMIS Neurosciences’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in ProMIS Neurosciences’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about ProMIS Neurosciences stock

On Eulerpool you can find the complete historical development of Debt ProMIS Neurosciences since 2006 – with annual values, charts, and detailed analysis.

Debt's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's ProMIS Neurosciences historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — ProMIS Neurosciences

All Key Metrics — ProMIS Neurosciences